Kazia Therapeutics Annual Report 2021

2021 AT A GLANCE Paxalisib is under investigation across a diverse range of brain cancers OUR PATIENTS Number of phase III clinical trials active globally Lung Cancer 184 Glioblastoma 13 Average survival from diagnosis with glioblastoma 12-18 months 4 distinct indications in phase II studies with paxalisib Glioblastoma, DIPG, primary CNS lymphoma, brain metastases SOURCE: clinicaltrials.gov SOURCE: National Brain Tumor Society > 150 patients treated with paxalisib worldwide to date Two best-in-class or first-in-class development candidates in clinical trials by end of CY2021 9 ongoing clinical trials with paxalisib OUR CLINICAL RESEARCH As at 30 June 2021 45 hospitals currently recruiting patients in GBM AGILE As at 30 June 2021 As at 30 June 2021 Kazia has grown rapidly, driven by progress in its world-class pipeline of cancer drug candidates OUR BUSINESS 80% of operating cashflows invested in R&D For FY2021 US$ 323M in potential milestone payments from outbound partnering deals 3 major cross-border licensing deals in FY2021 $24M of new equity capital raised through financing in FY2021 Kazia Therapeutics Limited 2 Annual Report 2021